Judge approves Anthem's $115M settlement for data breach

Anthem, Inc.'s $115 million settlement for a data breach that exposed the personal information of millions has been approved by a federal judge, according to a report by Bloomberg Law. 

In 2015, Anthem's system was breached, exposing the personal information of more than 78 people million. Information exposed included Social Security numbers, names, dates of births and healthcare ID numbers. 

According to the report, Anthem reached a settlement—without admitting any wrondoing—with about 19.1 million of its consumers in June. The agreement was approved by Judge Lucy Koh, of the U.S. District Court for the Northern District of California, on Aug. 15. 

"The settlement includes a pool of $15 million for consumers in the class group to claim up to $10,000 each for their out-of-pocket expenses related to correcting. The class members can also get free credit monitoring services beyond what Anthem has already offered," the report said. 

"In addition to the settlement fund, the health benefits company agreed to make changes to its data security procedures, including adopting encryption protocols for sensitive data."

To read the full report, click the link below. 

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.